As new treatments for dyslipidaemia such as cholesterol absorption inhibitors, bile acid sequestrants, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and fibrates are emerging [5, 41], future meta-analyses on CHM compared with various classes of lipid-lowering medications are worthy to establish an understanding of their roles in lipid metabolism. This evidence concerns the gene PCSK9 and inherited lipid metabolism disorder.